

A food-based dietary strategy lowers blood pressure in a low socio-economic setting: a randomised study in South Africa

Karen E Charlton^{1,2,*}, Krisela Steyn¹, Naomi S Levitt^{1,3}, Nasheeta Peer¹, Deborah Jonathan¹, Theresa Gogela¹, Katja Rossouw¹, Nomonde Gwebushe⁴ and Carl J Lombard⁴

¹Chronic Diseases of Lifestyle Unit, Medical Research Council, South Africa: ²School of Health Sciences, Faculty of Health and Behavioural Sciences, University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia: ³Division of Diabetes and Endocrinology, University of Cape Town: ⁴Biostatistics Unit, Medical Research Council, South Africa

Submitted 29 October 2007: Accepted 8 July 2008: First published online 27 August 2008

Abstract

Objective: To assess the impact of a food-based intervention on blood pressure (BP) in free-living South African men and women aged 50–75 years, with drug-treated mild-to-moderate hypertension.

Methods: A double-blind controlled trial was undertaken in eighty drug-treated mild-to-moderate hypertensive subjects randomised to an intervention (n 40) or control (n 40) arm. The intervention was 8-week provision of six food items with a modified cation content (salt replacement (SOLOTM), bread, margarine, stock cubes, soup mix and a flavour enhancer) and 500 ml of maas (fermented milk)/d. The control diet provided the same quantities of the targeted foods but of standard commercial composition and 500 ml/d of artificially sweetened cooldrink.

Findings: The intervention effect estimated as the contrast of the within-diet group changes in BP from baseline to post-intervention was a significant reduction of 6.2 mmHg (95% CI 0.9, 11.4) for systolic BP. The largest intervention effect in 24 h BP was for wake systolic BP with a reduction of 5.1 mmHg (95% CI 0.4, 9.9). For wake diastolic BP the reduction was 2.7 mmHg (95% CI -0.2, 5.6).

Conclusions: Modification of the cation content of a limited number of commonly consumed foods lowers BP by a clinically significant magnitude in treated South African hypertensive patients of low socio-economic status. The magnitude of BP reduction provides motivation for a public health strategy that could be adopted through lobbying of the food industry by consumer and health agencies.

Keywords
Randomised controlled trial
Sodium reduction
Potassium increase
Dietary intervention
Blood pressure
Hypertension
South Africans

In South Africa, the prevalence of hypertension in the adult black population is 24.4%. Diagnosis and management of the condition in this group is particularly poor^(1–5). The daily salt intake (7.8 g) in this group⁽⁶⁾ exceeds the recommended maximum of 6 g/d⁽⁷⁾ while K intake is low (between 50 and 60 mmol/d)^(8,9) and falls far below the intake that would be required to keep the Na:K ratio close to one, as recommended by the WHO⁽¹⁰⁾. Furthermore, low habitual dietary intakes have been reported for Ca and Mg⁽¹¹⁾. These data indicate a need for population-based approaches to change dietary behaviour for the prevention and management of hypertension.

The DASH trial provided evidence that a dietary pattern that is rich in fruit, vegetables and low-fat dairy products can reduce blood pressure (BP) significantly⁽¹²⁾. The follow-up DASH-Sodium study demonstrated additional

BP-lowering benefits of salt restriction over and above the merits of the DASH diet⁽¹³⁾.

In the South African context, promotion of the DASH eating plan is unrealistic due to high levels of food insecurity among the poor⁽¹⁴⁾ and the very low intake of fruit, vegetables and dairy products⁽¹⁵⁾. Identification of an affordable, sustainable and culturally acceptable dietary pattern is paramount to compliance in this group. It has been proposed that the way to lower salt intake on a population level is through the reduction of the Na content of processed foods^(16,17). Bread is a staple but also provides the highest proportion (41–73%) of non-discretionary Na in the diets of black South Africans⁽⁸⁾, thus is an obvious target. We hypothesise that a moderate reduction in Na intake, in the presence of an increased intake of K, Mg and Ca in commonly consumed foods,

will reduce BP significantly in black South Africans with hypertension.

Subjects and methods

We conducted a randomised, double-blind, controlled trial to investigate the impact of an 8-week feeding study (in which Na intake is decreased, and K, Mg and Ca intake is increased) on BP in mild-to-moderate hypertensive black South Africans (Fig. 1). The participants were black residents of a Cape Town township (Langa), aged 50–75 years, with drug-treated mild-to-moderate hypertension (systolic BP \leq 160 mmHg and diastolic BP \leq 95 mmHg) were eligible. Exclusion criteria included taking two or more diuretics; taking furosemide for cardiac failure; cerebral infarction or haemorrhage; renal impairment (serum creatinine $>$ 114.4 μ mol/l or creatinine clearance $<$ 50 ml/min (Cockcroft–Gault equation)⁽¹⁸⁾), three or more alcoholic drinks per day; type 1 diabetes mellitus; impaired cognitive function^(19,20); incontinence; and BMI $>$ 45 kg/m². Subjects with severely uncontrolled hypertension (i.e. $>$ 160/95 mmHg) were excluded. Those with uncontrolled diabetes and/or hypertension were referred to health-care providers during the run-in period.

Sample size calculations used the nQuery Advisor 5.0 program. Assuming a reduction in systolic BP of 6.3 mmHg,⁽²¹⁾ an SD of 10 mmHg, and a two group *t*-test with a 0.050 two-sided significance level and 80% power, a sample size of forty-one subjects per arm (*n* 82 in total) was required. The study was undertaken in two phases (May–December 2004 and January–July 2005). Recruitment and enrolment took place at a church-based setting and a community health centre, and advertisements were placed in the local community newspaper. Eligible subjects who completed a 3-week run-in period were randomised (Fig. 2).

In an industry–academia partnership, the Na content and K, Mg and Ca content were modified in five commonly consumed food items: brown bread, margarine, stock cubes, soup mixes and Aromat (monosodium glutamate-based flavour enhancer)⁽²²⁾. The intervention comprised these modified foods plus a salt replacement (SoloTM) and 500 ml of maas (fermented milk commonly eaten) daily. The control diet provided the same foods but of standard commercial composition, as well as artificially sweetened cold drink instead of maas. The subjects rated the palatability of trial foods using a 5-point Likert scale rating⁽²³⁾.

Subjects were instructed to consume their usual amounts of food⁽⁸⁾ and sufficient food was provided for the whole family. Based on laboratory-determined chemical food analyses, compared to control foods, the intervention foods were planned to provide 41% less Na (100.3 *v.* 170.3 mmol/d), 826% more K (70.9 *v.* 8.6 mmol/d), 388% more Ca (857 *v.* 221 mg/d) and 368% more Mg (13.8 *v.* 3.7 mmol/d).

Both study participants and fieldworkers were blinded to diet group allocation of subjects. A single dietitian was responsible for food-packing and all food was locked and sealed in large shopping bags, labelled only with participants' names and contact details. A driver delivered the food three times a week.

Clinical measurements and biological samples were taken and questionnaires administered by trained fieldworkers in either Xhosa or English before, during and after the intervention at the time points, as shown in Fig. 1. Height was recorded using a stadiometer and weight recorded on a calibrated scale, to the nearest 100 g. BMI was calculated as weight (kg)/(height (m))². Body fat was measured using a standard tetrapolar 50 kHz bioimpedance monitor (BodystatTM), with the subject lying supine. The prediction equations include body weight, height, age and gender.

Urinary and fasting blood parameters were analysed by National Health Laboratories Institute, based at Groote Schuur Hospital, using standard methods and quality




Fig. 1 Scheme of study design (BP, blood pressure)




Fig. 2 Recruitment and screening of subjects

control procedures. Completeness of 24 h urine collection was assessed as at least 500 ml volume and a urinary creatinine value ≥ 0.18 mmol/kg lean body mass/d for men or ≥ 0.12 mmol/kg lean body mass/d for women⁽²⁴⁾. Urinary analyses included Na, K, Mg, Ca and creatinine.

A questionnaire included sociodemographic data, medical history and self-perceived health status using an adapted EQ-5D instrument⁽²⁵⁾. Subjects were asked to bring all prescribed medications for recording by trained nurses. Subjects completed interviewer-administered 24 h dietary recalls⁽²⁶⁾ using the South African validated Dietary Assessment Education Kit⁽²⁷⁾ to quantify food portion sizes. Recorded foods were converted to gram weights and daily nutrient intake using the Medical Research Council (MRC) Food Quantities Manual⁽²⁸⁾ and Foodfinder III computerised dietary assessment program based on national food tables⁽²⁹⁾. Dietary compliance was monitored using data from 24 h recalls and 24 h urinary electrolyte concentrations, and returned salt and Aromat shakers were weighed weekly. Physical activity levels were measured using the Yale Physical Activity Survey instrument⁽³⁰⁾.

The primary outcome variable was resting office BP, measured according to the American Heart Association Recommendations for BP Determination⁽³¹⁾, using a validated automated method with pre-set inflation⁽³²⁾ (Omron M4-I BP monitor; Omron Matsusaka Co., Ltd, Japan). A large cuff was used for arm circumferences ≥ 33 cm. BP was measured three times on each occasion and an average of the second and third measurements taken for analyses. BP was measured weekly four times before the initiation of the intervention and the mean taken as baseline BP ('Pre'). Thereafter, BP was measured on two occasions each at weeks 4 and 8.

In addition, average 24 h ambulatory systolic and diastolic BP and awake and asleep BP were measured at

baseline and during the final week of the intervention, using an Oscar 2 (SunTech Medical) Ambulatory Blood Pressure Monitor (ABPM), which has been validated and endorsed by the British Hypertension Association as being reliable for use in clinical trials⁽³³⁾.

The Research and Ethics Committee of the University of Cape Town approved the study protocol. The trial was registered with the South African Department of Health National Research Register (DOH-27-0806-1394). Written informed consent was obtained from all participants who were closely monitored for adverse effects.

Intention-to-treat analyses were performed. For analysis of office (Omron) BP, linear regression was performed to assess the intervention effect at weeks 4 and 8. The model had indicators for diet group, phase, time and interaction effects for testing the consistency of the intervention effect over the two phases and the expected differential change in BP over time in the two diets. The analysis accounted for the repeated nature of the BP measurements within each subject by using the generalised estimation equation (GEE) approach. From this model, a contrast in Omron BP measurements for the change from baseline to the intervention period between the diet groups was estimated. Using a method described by Rochan (1995)⁽³⁴⁾ to adjust for a covariate which is observed post-randomisation, a seemingly unrelated regression analysis was used to model the BP outcomes and change to anti-hypertensive medication (yes or no response) on diet group and phase. The SUR program of STATA was used for this analysis.

For analysis of 24 h ABPM, multivariate linear regression was used to assess the intervention effect. The vector of 24 h ABPM measurements (systolic and diastolic BP for average, wake, sleep and mean arterial pressure (MAP)) obtained at the end of the intervention period was

modelled on indicator variables for diet and phase as well as the baseline values of average 24 h systolic and diastolic BP and 24 h MAP. The intervention effect with 95% CI was estimated for the pooled data. Regression analyses were also conducted using the SUR model in order to account for medication change as a post-randomisation covariate.

Change in other variables between baseline and post-intervention was assessed using paired *t*-tests within diet groups. Between-diet group differences were investigated using independent *t*-tests. Multivariate linear regression modelling for change in systolic and diastolic BP included the following variables in the model: change in 24 h urinary excretion of Na, K, Mg and Ca; diet group; and the interaction effects of diet and urinary cation changes.

Results

During the intervention, one subject each in the intervention and control groups dropped out and one intervention group participant had a stroke, leaving eighty subjects (*n* 40 per diet group; Fig. 2). Baseline sociodemographic characteristics, BP and lifestyle factors associated with BP control are shown in Table 1. Mean age was 61.7 (SD 7.9) years and the control group was on average 5 kg heavier than the intervention group.

The average number of prescribed anti-hypertensive medications was 2.1 (SD 0.9) with the most common medication being low-dose thiazide diuretics (76.2% participants), followed by ACE inhibitors (55.0%). Thirty per cent were on monotherapy.

Table 1 Baseline sociodemographic characteristics of the sample, lifestyle factors associated with hypertension control and self-perceived health status

	Intervention (<i>n</i> 40)		Control (<i>n</i> 40)		<i>P</i> -value†
	Mean	SD	Mean	SD	
Age (years)	61.8	6.6	60.4	7.4	0.355
Range	50–76		50–75		
Female/male ratio	33/7		34/6		
Literacy rate (ability to read) (%)	97.5		95.0		0.222
Highest level of education achieved (<i>n</i>)					0.280
≤7 years of schooling (primary)	10		15		
8–12 years of schooling (secondary)	26		20		
Tertiary/diploma	4		5		
Employment status (<i>n</i>)					0.740
Employed	5		8		
Unemployed/housewife	12		10		
Social (old age) grant	21		18		
Disability grant	2		4		
Type of housing (<i>n</i>)					0.070
Formal housing (privately owned)	17		20		
Council/core house	13		4		
Informal shack	2		8		
Hostel	8		8		
Housing density (no. of persons/no. of rooms)	2.77	1.96	2.48	1.71	0.543
Previously diagnosed chronic conditions (<i>n</i>)					
Heart attack or angina	6		3		0.289
Any other heart condition	4		2		0.396
Hypercholesterolaemia	1		3		0.305
Asthma	6		3		0.762
Peripheral vascular disease	2		2		1.000
Diabetes*	7		7		0.556
Self-rated health scale					0.355
Mean score	65.7	19.0	65.4	20.7	
Range	10–100		30–100		
Tobacco use (<i>n</i>)					0.404
Current tobacco use	4		3		
Past smoker	2		0		
Physical activity (kJ/week)	7641	5074	8502	6496	0.329
Weight (kg)	83.3	13.7	88.8	15.5	0.990
BMI (kg/m ²)	32.9	5.8	35.3	6.0	0.077
Lean mass (%)	54.7	9.1	51.9	9.0	0.964
Fat mass (%)	45.3	9.1	48.1	9.0	0.183
Systolic BP (mmHg)	133.9	14.6	135.4	16.7	0.666
Diastolic BP (mmHg)	79.8	8.6	82.3	7.5	0.180
Average 24 h systolic BP (mmHg)	135.0	13.5	138.9	17.0	0.254
Average 24 h diastolic BP (mmHg)	79.2	8.7	80.4	8.9	0.547

BP, blood pressure.

*Data obtained from medication history during run-in period, plus one newly diagnosed diabetic in low salt group of phase 1.

†Independent *t*-test for difference between groups; Fisher's exact test for categorical data.




Fig. 3 (a) Mean systolic blood pressure (BP) (Omron) at baseline (week 0), week 4 and week 8 of intervention, according to diet group allocation (error bars reflect SEM). (b) Mean diastolic BP (Omron) at baseline (week 0), week 4 and week 8 of intervention, according to diet group allocation (error bars reflect SEM) (—▲—, control; —■—, low salt)

Compared to mean Omron BP at baseline, mean values estimated at weeks 4 and 8 are shown in Fig. 3. The figure demonstrates that most of the intervention effect had already occurred within the first 4 weeks of the intervention. No significant difference was found in change from baseline between weeks 4 and 8 for both systolic and diastolic BP (results not shown). The average BP of weeks 4 and 8 ('Post') is shown in Fig. 4. The estimated intervention effects, which included diet and phase in the regression modelling, are shown in Table 2. Mean post-intervention Omron systolic BP in the intervention group was 6.2 mmHg ($P=0.021$) lower than in the control




Fig. 4 Mean systolic and diastolic blood pressure (BP) at pre (baseline) and post (mean of week 4 and week 8 measurements), according to diet group allocation (error bars reflect SEM) (—▲—, control; —■—, low salt)

group with no significant between-group difference in diastolic BP. For ABPM the significant reduction in average (4.5 mmHg) and wake (5.1 mmHg) systolic BP was also due to the intervention.

The SUR modelling, which adjusted for medication change (yes or no), provided similar results but found a mean between-group change in systolic BP from baseline to post-intervention of -6.43 mmHg (95% CI -11.2 , -1.7 ; $P=0.008$) and a non-significant change in diastolic BP of -0.988 mmHg (95% CI -3.23 , 1.47 ; $P=0.464$). For 24 h BP, diet-related reductions in average systolic and diastolic BP were both significant ($P<0.05$) at -4.91 mmHg (95% CI -9.2 , -0.7) and -2.65 mmHg (95% CI -5.13 , -0.17), respectively. Change in systolic BP during waking hours was the 24 h BP parameter found to have the greatest reduction associated with the intervention effect (mean = -5.59 (SEM = 2.31) mmHg; $P=0.015$).

Twenty-two subjects (n 13 (intervention); n 9 (control)) had a change in anti-hypertensive medication during the trial. No significant difference in the profile of medication change (i.e. medications added (n 11); removed (n 6); combination of both (n 5); or no change (n 58)) was found between diet groups (Fisher's exact test; $P=0.095$). At baseline, there was no difference in systolic BP between those who had no change to their anti-hypertensive medication during the trial (n 58) and those who did have medication changes (n 22) (133.8 (SD 16.8) *v.* 137.0 (SD 11.9) mmHg, respectively; $P=0.2105$).

Table 2 Estimated intervention effects for office BP and 24 h ABPM

	Mean net difference* (mmHg)	SEM	95% CI of difference		P-value of contrast
			Lower	Upper	
Office BP (Omron)					
Systolic BP	-6.194†	2.636	-11.442	-0.945	0.021
Diastolic BP	-0.595†	1.216	-3.019	1.829	0.626
24 h ABPM					
Average systolic BP	-4.527‡	2.269	-9.047	-0.006	0.050
Average diastolic BP	-2.494‡	1.338	-5.160	0.173	0.066
Wake systolic BP	-5.138‡	2.404	-9.928	-0.348	0.036
Wake diastolic BP	-2.661‡	1.457	-5.565	0.242	0.072
Sleep systolic BP	-3.465‡	2.540	-8.527	1.596	0.177
Sleep diastolic BP	-1.790‡	1.679	-5.134	1.555	0.290
MAP	-3.113‡	1.583	-6.267	0.040	0.053

BP, blood pressure; ABPM, ambulatory blood pressure monitor; MAP, mean arterial pressure.

*Low-salt - control.

†Contrast between groups of pre to post changes. Pre = mean of run-in visits (1, 2, 3) and visit 4 (day 1 of intervention); post = mean of week 4 and week 8 measurements.

‡Contrast between groups at week 8 adjusted for baseline covariates.

Table 3 Reported daily dietary intake at baseline and during the intervention, according to diet group (values are in mean and SD)

Nutrient	Baseline		Post		Difference†		Mean difference (intervention-control)		
	Mean	SD	Mean	SD	Mean	SD	P-value*	Mean	SD
Energy (kJ)									
Intervention	6441	1569	7370	2075	929	1840	0.0267	-145	1973
Control	6433	1903	7505	2436	1074	2186	0.0309		
Protein (g)									
Intervention	54	16	62	20	8	18	0.0488	6.5	26.3
Control	57	30	59	20	1.5	25.2	0.7933		
Fat (g)									
Intervention	48	18	52	19	4.3	18.4	0.3039	-2.6	24.7
Control	51	23	57	25	6.8	23.9	0.2043		
Carbohydrate (g)									
Intervention	200	55	247	85	46	72	0.0051	-5.6	77.8
Control	194	60	246	96	52	80	0.0049		
Na (mg)‡									
Intervention	1694	724	1778	916	85	826	0.6487	-1167	1532*
Control	1912	922	3164	1757	1252	1403	0.0002		
Ca (mg)‡									
Intervention	385	180	822	353	436	280	<0.0001	310	392**
Control	407	298	533	377	126	340	0.1009		
K (mg)‡									
Intervention	1832	517	2729	977	897	781	<0.0001	867	890***
Control	1826	588	1857	799	31	707	0.8420		
Mg (mg)‡									
Intervention	223	64	307	103	84	86	<0.0001	71	89**
Control	222	65	235	91	14	79	0.4446		

Baseline = average of visits 1, 2 and 3 during run-in; Post = average of weeks 4 and 8.

* $P < 0.01$; ** $P < 0.001$; *** $P < 0.0001$ for differences between diet groups.

†Difference = Post - Baseline.

‡For conversion to mmol/d, divide by following factors: 23 (Na); 40 (Ca); 39 (K); 24 (Mg).

Similarly, there was no baseline difference in 24 h systolic BP between groups that had medication changes compared to those that did not (135.6 (SD 15.6) *v.* 140.4 (SD 3.1) mmHg, respectively; $P = 0.1061$). Results for diastolic BP were similar.

There were no baseline differences in reported food intake patterns between the two groups. During the intervention, in both groups reported energy and carbohydrate intake increased significantly but reported protein, fat and cholesterol intake remained unchanged. Reported dietary Na intake increased in the control

group, but was unchanged in the intervention group (Table 3). Reported K, Ca and Mg intake significantly increased in the intervention group, but not in the control group. A significant between-group difference was found for change in intake between intervention and baseline for Na, K, Ca and Mg. Mean difference in Na/4200 kJ was a reduction of -104 (SD 418) mg/4200 kJ for the intervention group and an increase of 558 (SD 1058) mg/4200 kJ for the control group, yielding a net between-diet difference of -661 (SD 805) mg/4200 kJ ($P = 0.0006$). The significant mean increase of dietary Ca intake of 310 mg/d

Table 4 Mean and SD 24 h urinary excretion of Na, K, Mg and Ca (mmol/d)

Diet group	Baseline		Post-intervention		Mean change from baseline†		Mean between-diet group difference‡	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Urinary Na (mmol/24 h)								
Intervention	171.7	53.7	154.3	64.0	-14.6	54.4	-8.7	46.9
Control	173.2	52.4	169.3	57.7	-5.9	54.3		
Urinary K (mmol/24 h)								
Intervention	52.3	11.0	71.7	25.5	+20.0	22.7**	+24.6	16.5**
Control	52.9	14.7	48.6	14.3	-4.6	14.8		
Urinary Mg (mmol/24 h)								
Intervention	2.86	0.93	3.70	1.57	+0.88	1.20	+0.68	0.88*
Control	2.79	0.96	3.00	1.07	+0.19	0.81		
Urinary Ca (mmol/24 h)								
Intervention	1.92	1.35	2.15	1.61	+0.27	1.00	-0.05	0.91
Control	1.39	1.72	1.72	1.65	+0.32	1.11		

Baseline = Average of run-in visits 1,2,3; Post = average of weeks 4 and 8.

* $P < 0.05$; ** $P < 0.001$.

†Baseline minus Post.

‡Intervention diet minus Control.

in the intervention compared to the control group was explained by a reported increased intake of maas from 33 g/d at baseline to 275 g/d in the intervention group.

There were no between-group differences for the household quantity of either salt or Aromat used during the trial. The low-salt margarine (87.5%) and the salt replacement (75%) were reported to taste less acceptable than the normal products; however, other intervention food items were preferred to the regular consumed varieties. The control group reported that they preferred all of the food items provided, despite the fact that the foods were unaltered in cation content.

The 24 h urinary excretion data found that there was a trend for a reduced Na excretion in the intervention group, but this was not significantly lower than that of the control group (Table 4). Significant between-group differences after the intervention were found for urinary K and Mg excretion with no change in urinary Ca excretion.

No change between baseline and end of intervention was found for weight, BMI, % body fat, self-perceived health status score or physical activity in either the groups.

Discussion

This study demonstrates a public health intervention that can achieve a clinically significant reduction in systolic BP in moderately hypertensive subjects on treatment living in a low-income community setting in South Africa through the dietary manipulation of seven commonly consumed processed foods. The study also illustrates that this will require partnerships between public health agencies and the food industry.

An important difference between the design of our study and that of other food-based BP trials^(12,13,35,36) is that we did not attempt to alter habitual food patterns, in either quantity or quality.

The BP-lowering effect we found for systolic BP was similar to or higher than responses reported in meta-

analyses of randomised trials of either Na reduction (n 40 trials) or K supplementation (n 27 trials)⁽³⁷⁾. Our results are also similar to the findings of a 24-week randomised trial in 55–75-year-old untreated Dutch hypertensives in which the same salt replacement product was used⁽³⁸⁾. The DASH 8-week feeding study, however, demonstrated a much greater BP reduction ($-13.2/-6.1$ mmHg) in the subgroup analyses for African-Americans with hypertension⁽¹³⁾. All food and beverages were provided in the DASH study and subjects consumed one supervised meal a day at the research centre, thus enhancing compliance. In trials such as PREMIER⁽³⁶⁾, where patients are required to follow the DASH diet while purchasing their own food, the recommended number of daily servings of fruit and vegetables could not be met. Few food-based trials have been conducted in developing countries. A randomised 8-week crossover study of low-salt and high-salt intakes conducted in Jamaica and Nigeria demonstrated a mean between-diet change in systolic BP of approximately 5 mmHg in both country sites⁽³⁹⁾. In the Nigerian site, participants were able to achieve substantial Na reductions by simply not adding salt during meal preparation.

The dietary intervention achieved an overall increase in K, Mg and Ca but surprisingly without a substantial decrease in the Na content of the diet, at least according to the urinary excretion results. The intervention diet was calculated to provide a decrease in dietary Na intake of 70 mmol/d, compared to the control diet (41% reduction). The 24 h dietary recall data found a significant increase in energy and carbohydrate intake in both diet and control groups, explained by increased bread consumption in both groups during the trial. It appears that the increased bread intake displaced other staple foods, notably maize meal, to which large quantities of salt are generally added (de Goede J, van der Meij B (2001) Risk factors of obesity in black, female Community Health Workers living in an urban area in South Africa. M.Sc. Dissertation. Wageningen UR, unpublished).

The discrepancies between the urinary excretion and dietary intake data may be related to methodological difficulties associated with the collection of both these variables. The dietary data found a significant between-group reported difference in Na intake of 51 mmol/d, and this difference remained even after controlling for an increased energy intake during the intervention.

It was not the purpose of this study, nor was it powered, to determine the contribution of each dietary manipulation (i.e. decreased Na and increased K, Mg and Ca) to BP reduction, but rather to demonstrate effectiveness of a practical composite dietary approach that could be of public health significance in the target population. However, regression modelling suggests that increased urinary K excretion contributed most to the BP-lowering impact of the intervention (data not shown).

Dairy foods are an important component of the DASH diet⁽¹²⁾ and Ca supplementation is associated with a modest reduction in BP (average of $-1.86/-0.99$ mmHg) with a slightly higher reduction in people with Ca intakes below 800 mg/d ($-2.63/-1.30$ mmHg)⁽⁴⁰⁾. In the present study, participants in the intervention group did not manage to consume the recommended additional 500 g of maas (fermented milk)/d that was provided and reported about half of this intake, presumably because it was shared with other household members. It is recommended that further dietary BP studies be conducted in populations with habitually low-Ca intakes, to compare the BP-lowering effect of an increased intake of dairy foods as compared to other strategies such as Na reduction.

In effect, our trial simulated the high-Na arm (150 mmol Na/d) of the DASH-Sodium trial⁽¹⁵⁾. Urinary K excretion of subjects in the low-salt arm increased during the trial to similar levels as described for subjects following the DASH diet in both the original DASH study (74.5 mmol/d) and the follow-up DASH-Sodium study (75.0 mmol/d). Urinary Mg levels rose to similar concentrations (4.03 mmol/d), but urinary Ca was considerably lower than DASH study participants (3.64 mmol). We achieved similar BP reductions between diet-control groups as those reported in participants in the high-Na arm of the DASH-Sodium study. Thus, simply by changing the cation content of five commonly eaten foods, providing a salt replacement, and the daily addition of a fermented milk drink, the effects of the DASH diet can be achieved in South African black treated hypertensive subjects who consume a high salt intake.

On a population level, it is estimated that the BP-lowering effect of this dietary intervention would result in a 20% reduction in the number of deaths attributed to high BP, preventing more than 9000 deaths in one year (Rosana Norman, personal communication, based on secondary analysis of the South African Demographic and Health Survey data⁽⁴¹⁾ to estimate the disease burden attributable to high BP in South Africa for the year 2000⁽⁴²⁾).

A limitation of the study is that the intervention effect was calculated using the mean of four repeated

measurements for the baseline measure and the mean of only two repeated measurements (week 4 and week 8) as the 'post' BP measure. The large variability in BP change far exceeded that reported in the DASH study⁽⁴³⁾.

The study aimed to demonstrate effectiveness of a community-based dietary intervention, rather than its efficacy; therefore, only treated hypertensives were included in the study. We considered it to be unethical to ask participants to stop their anti-hypertensive medication for almost 6 months since the target population is known to be at high risk of cerebrovascular disease. It is logistically not feasible to recruit a sample of untreated hypertensives in the South African context and in reality most hypertensive patients will be taking anti-hypertensive medication when they start making dietary changes to further improve their BP control. In line with the national guidelines for the management of hypertension in the primary health-care setting that recommend diuretic agents as the first-line drug for all patients with hypertension^(44,45), 86% of participants were being prescribed diuretics with thiazide-type diuretics, the cheapest anti-hypertensive agent available, being the most commonly used agent. Individuals who were taking more than one diuretic were excluded as this is considered to be inappropriate management, based on national and international therapeutic guidelines. Our inclusion strategy is in line with international drug trials in hypertension that currently enter patients already on multiple anti-hypertensive drugs, such as the VALUE Trial⁽⁴⁶⁾.

The change in BP medication during the trial was similar between the intervention and control groups and did not impact on the study outcomes. The reported results provide pragmatic estimates of the effect of the intervention in general, including the effect over time (the study was conducted in two phases) and the effect over all medication adjustments. The important message from this trial conducted in a low-income community setting is that, regardless of medication change, changes in diet can have beneficial outcomes for systolic BP.

Generalisability of the results warrants consideration. To facilitate the practical delivery of the foods, participants were recruited from only one geographical area, Langa, one of the oldest and more established peri-urban townships of Cape Town, which has an estimated population of 46 505, mostly Xhosa-speaking Africans⁽⁴⁷⁾. Good BP control is rarely achieved in this high-risk group which may be attributed to socio-economic factors, such as failure to return to health-care centres for follow-up visits due to transport costs and time involved, patients' lack of knowledge of the disease and its outcomes, and poor service delivery at primary health-care level in South Africa^(48,49). Extrapolation of the findings to the normotensive population and to those with severe hypertension cannot be assumed. Similarly, the inclusion of mostly obese women, and few men, limits the generalisability of the results to other sectors of the target population.

Further, the relatively short duration of the trial (8 weeks) raises questions regarding compliance with the dietary changes over the longer term.

Conclusion

This randomised controlled trial provides evidence that manipulation of the Na, K and Mg content of commonly consumed processed foods, together with the provision of a salt replacement and daily consumption of 500 ml fermented milk, lowers BP in free-living, black South Africans with moderate hypertension who were using medication. The South African food industry needs to be lobbied by consumers, the Department of Health and other health agencies to lower the Na content of their products (preferably while concurrently increasing K), particularly in staple foods such as bread, in order to lower BP.

Acknowledgements

Sources of funding: This study was funded by a doctoral fellowship provided by Unilever South Africa Foods and by additional financial support from Sasko Bakeries (Division of Pioneer Foods, South Africa) and research grants provided by the South African MRC, the Circulatory Diseases Research Fund, the South African Hypertension Society and the THRIP initiative of the National Research Foundation. The experimental bread was developed and provided free-of-charge by Sasko Bakeries. Unilever South Africa provided, free-of-charge, the control and intervention margarine, stock cubes, soup mixes and Aromat. SOLO™ salt replacement was donated by the Low Sodium Sea Salt Co. Ltd. (UK). The study funders had no role in the study design, nor in the collection, analysis or interpretation of the data.

Conflict of interests: There are no conflicts of interests.

Authorship contributions: K.E.C., the principal investigator, was responsible for conceptualisation and design of the study, participated in the collection, analysis and interpretation of the data and was overall responsible for writing the paper. K.S. and N.S.L. participated in the conceptualisation and design of the study, and in the collection, analysis and interpretation of the data. N.P. supervised the fieldwork and data collection and collected the ABPM measurements. K.R. packed the food items and performed dietary analyses, data coding and data entry. T.G. and D.J. were responsible for participant recruitment, fieldwork planning and data collection. N.G. participated in statistical analysis of the data. C.J.L. performed sample size calculations, randomisation of participants, and was responsible for the primary statistical data analysis.

Acknowledgements: Ms Ria Laubscher is thanked for the dietary analyses and Ms Jean Fourie for typesetting the questionnaires.

References

1. Steyn K, Gaziano TA, Bradshaw D, Laubscher R & Fourie J (2001) Hypertension in South African adults: results from the Demographic and Health Survey, 1998. *J Hypertens* **19**, 1717–1725.
2. Moodley J, Steyn K, Ehrlich R, Jordaan E, Marais AD & Burgess L (1997) Lipid and ischaemic heart disease risk factors in an urbanising work force. *S Afr Med J* **87**, 1615–1620.
3. Steyn K, Fourie J, Lombard C, Katzenellenbogen J, Bourne L & Jooste P (1996) Hypertension in the black community of the Cape Peninsula, South Africa. *East Afr Med J* **73**, 758–763.
4. Mollentze WF, Moore AJ & Steyn AF (1995) Coronary heart disease risk factors in a rural and urban Orange Free State black population. *S Afr Med* **85**, 90–96.
5. Seedat YK (1999) Hypertension in black South Africans. *J Hum Hypertens* **13**, 96–103.
6. Charlton KE, Steyn K, Levitt NS, Zulu J, Jonathan D, Veldman D & Nel JH (2005) Ethnic differences in intake and excretion of sodium, potassium, calcium and magnesium in South Africans. *Eur J Cardiovasc Prev Rehabil* **12**, 355–362.
7. National High Blood Pressure Education Program (2003) *The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure*. NIH Publication no. 03-5231. Washington, DC: US Department of Health and Human Services.
8. Charlton KE, Steyn K, Levitt NS, Zulu JV, Jonathan D, Veldman FJ & Nel JH (2005) Diet and blood pressure in South Africa: the intake of foods containing sodium, potassium, calcium and magnesium in three ethnic groups. *Nutrition* **21**, 39–50.
9. Matlou SM, Isles CG, Higgs A, Milne FJ, Murray GD, Schultz E & Starke IF (1986) Potassium supplementation in blacks with mild to moderate essential hypertension. *J Hypertension* **4**, 61–64.
10. World Health Organization/Food and Agricultural Organization Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (28 January–1 February 2002) Background paper on the scientific basis for diet, nutrition and the prevention of cardiovascular disease (Annex 4). Geneva: WHO.
11. Vorster HH, Oosthuizen W, Jerling JC, Veldman FJ & Burger HM (1997) *The Nutritional Status of South Africans. A Review of the Literature from 1975–1996*. Durban: Health Systems Trust.
12. Appel L, Moore T, Obarzanek E *et al.* (1997) A clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med* **336**, 1117–1124.
13. Sacks FM, Svetky LP, Vollmer WM *et al.*, for the DASH-Sodium collaborative research group (2001) Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. *New Engl J Med* **1**, 3–10.
14. Charlton KE & Rose D (2002) Prevalence of household food poverty in South Africa: results from a large nationally representative survey. *Publ Health Nutr* **5**, 383–389.
15. Steyn NP, Bradshaw D, Norman R, Joubert J, Schneider M & Steyn K (2006) *Dietary Changes and the Health Transition in South Africa: Implications for Health Policy*. Cape Town: South African Medical Research Council.
16. Greenfield H, Smith AM, Maples J & Wills RBH (1984) Contributions of foods to sodium in the Australian food supply. *Hum Nutr Appl Nutr* **38**, 203–210.
17. Williams P, McMahon A & Boustead R (2003) A case study of sodium reduction in breakfast cereals and the impact of the Pick the Tick food information program in Australia. *Health Promot Int* **18**, 51–56.
18. Cockcroft DW & Gault MH (1976) Prediction of creatinine clearance from serum creatinine. *Nephron* **16**, 31–41.

19. Broderick K (2002) Correlation between scores on two screening tools for dementia in Xhosa women. *S Afr J Occup Ther* **32**, 8–13.
20. Brooke P & Bullock R (1999) Validation of a 6-item Cognitive Impairment Test with a view to primary care usage. *Int J Geriatr Psychol* **14**, 936–940.
21. Midgely JP, Matthew AG, Greenwood CMT & Logan AG (1996) Effect of reduced dietary sodium on blood pressure. *J Am Med Assoc* **275**, 1590–1597.
22. Charlton KE, MacGregor E, Vorster N, Levitt NS & Steyn K (2007) Partial replacement of NaCl can be achieved with K, Mg and Ca salts in brown bread. *Int J Food Sci Nutr* **58**, 508–521.
23. Drewnowski A, Ahlstrom Henderson S, Driscoll A & Rolls BJ (1996) Salt taste perceptions and preferences are unrelated to sodium consumption in healthy older adults. *Am J Clin Nutr* **96**, 471–474.
24. Laposta M (1992) *SI Conversion Guide*. Boston, MA: New England Journal of Medicine (NEJM) Books.
25. Jelsma J, Mkoka S, Amosun L & Nieuwveldt J (2004) The reliability and validity of the Xhosa version of the EQ-5D. *Disabil Rehabil* **26**, 103–108.
26. Gibson R (2002) Dietary assessment. In *Essentials of Human Nutrition*, 2nd ed., pp. 449–466 [J Mann and AS Truswell, editors]. Oxford: Oxford University Press.
27. Steyn NP & Senekal M (2004) *The Dietary Assessment and Education Kit (DAEK)*. Parow: Medical Research Council.
28. Langenhoven MJ, Conradie PJ, Wolmarans P & Faber M (1991) *MRC Food Quantities Manual*, 2nd ed. Tygerberg: Medical Research Council.
29. Langenhoven M, Kruger M, Gouws E & Faber M (1991) *MRC Food Composition Tables*, 3rd ed. Parow: Medical Research Council.
30. Dipietro L, Caspersen CJ, Ostfield AM & Nadel ER (1993) A survey for assessing physical activity among older adults. *Med Sci Sports Exerc* **25**, 628–642.
31. Perloff D, Grim C, Flack J *et al.* (1993) Human blood pressure determination by sphygmomanometry. *Am J Hypertens* **88**, 2460–2467.
32. Altunkan S, Ilman N, Kayatürk N & Altunkan E (2007) Validation of the Omron M6 (HEM-7001-E) upper-arm blood pressure measuring device according to the International Protocol in adults and obese adults. *Blood Press Monit* **12**, 219–225.
33. Goodwin J, Bilous M, Winship S, Finn P & Jones SC (2007) Validation of the Oscar 2 oscillometric 24-h ambulatory blood pressure monitor according to the British Hypertension Society protocol. *Blood Press Monit* **12**, 113–117.
34. Rochan J (1995) Supplementing the intent-to-treat analysis: accounting for covariates observed postrandomization in clinical trials. *J Am Statist Assoc* **90**, 292–300.
35. Miller ER III, Erlinger TP, Young RD *et al.* (2002) Results of the Diet, Exercise and Weight Loss Intervention Trial (DEW-IT). *Hypertension* **40**, 612–618.
36. Writing Group of the PREMIER Collaborative Research Group (2003) Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA* **16**, 2083–2093.
37. Geleijnse JM, Witteman JCM, Bak AAA, den Breeijen JH & Grobbee DE (1994) Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. *Br Med J* **309**, 436–440.
38. Geleijnse JM, Kok FJ & Grobbee DE (2003) Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. *J Hum Hypertens* **17**, 471–480.
39. Forester T, Adeyamo A, Soarres-Wynter S *et al.* (2005) A randomized trial on sodium reduction in two developing countries. *J Hum Hypertens* **19**, 55–60.
40. van Mierlo LA, Arends LR, Streppel MT, Zeegers MP, Kok FJ, Grobbee DE & Geleijnse JM (2006) Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. *J Hum Hypertens* **20**, 571–580.
41. Department of Health, Medical Research Council and Macro International (2002) *South African Demographic and Health Survey 1998. Full Report*. Pretoria: Department of Health.
42. Norman R, Gaziano T, Laubscher R, Steyn K & Bradshaw D (2007) Estimating the burden of disease attributable to high blood pressure in South Africa in 2000. *S Afr Med J* **97**, Part 2, 692–698.
43. Vollmer WM, Appel LJ, Svetkey LP *et al.* (2005) Comparing office-based and ambulatory blood pressure monitoring in clinical trials. *J Hum Hypertens* **19**, 77–82.
44. Milne FJ, Pinkney-Atkinson VJ & South African Hypertension Society of Hypertension Guideline Working Groups 2000 and 2003 (2004) Hypertension guideline 2003 update. *S Afr Med J* **94**, 209–216, 218, 220–225.
45. Opie LH & Steyn K (1995) Rationale for the hypertension guidelines for primary care in South Africa. *S Afr Med J* **85**, 1325–1338.
46. Weber MA, Julius S, Kjeldsen SE *et al.* (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. *Lancet* **363**, 2049–2051.
47. Statistics South Africa (1996) *Census Data from Urban Policy Unit*. Pretoria: Statistics South Africa.
48. Hale LA, Fritz VU & Eales CJ (1998) Do stroke patients realise that a consequence of hypertension is stroke? *S Afr Med J* **88**, 451–454.
49. Daniels A, Biesma R, Otten J, Levitt NS, Steyn K, Martell R & Dick J (2000) Ambivalence of primary health-care professionals towards the South African guidelines for hypertension and diabetes. *S Afr Med J* **90**, 1206–1211.